Home / Market News / $NAUT
benzinga Corporate Catalyst Impact 65/100 ● neutral

Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Sep 29, 2026, 9:31 AM UTC · Primary ticker $NAUT

Roth Capital has initiated coverage on Nautilus Biotechnology (NAUT) with a 'Buy' rating and a price target of $3.5. This analyst coverage provides a new valuation perspective and could generate increased investor interest in the company.

Roth Capital analyst Max Masucci has initiated coverage on Nautilus Biotechnology (NAUT) with a 'Buy' rating and a price target of $3.5. This event is significant as new analyst coverage, especially with a positive rating, can often lead to increased visibility and investor confidence in a stock. For NAUT, this could translate into short-term positive price movement as investors react to the new valuation and endorsement. Long-term implications depend on the company's ability to meet or exceed the analyst's expectations and execute on its business strategy. The key opportunity for traders is the potential for an upward price adjustment following the initiation of coverage.

$NAUT positive New 'Buy' rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.